Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates

Beam Therapeutics (BEAM) reported a loss of $1.09 per share for the fourth quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of $1.10. The company had recorded earnings of $1.73 per share in the year-ago quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.Total revenues, comprising license and collaboration revenues, came in at $30.1 million in the fourth quarter compared with $316.2 million reported in the year-ago period. The top line beat the Zacks Co ...